Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2008

Nonprofit Organization Receives License for Anti-HIV Candidate from Merck & Co.

  • Merck & Co. will provide a royalty-free license to the International Partnership for Microbicides (IPM) to develop an antiretroviral compound for use as a vaginal microbicide.

    The compound, called L'644, is a member of a class of antiretroviral molecules known as gp41 fusion inhibitors, which inhibit HIV infection by preventing the virus from fusing with the surface of target cells.

    Under the terms of the agreement, Merck grants IPM the rights to develop L'644 in developing countries. The firm will collaborate with IPM to advance early-stage development research efforts.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »